Respiratory Syncytial Virus Infection clinical trials

Explore recruiting respiratory syncytial virus infection clinical trials.

Recruiting respiratory syncytial virus infection studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Respiratory Syncytial Virus Infection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of MK-3508 in Healthy Participants

Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants

Romania, Finland, France, Italy, Denmark, Poland +1 more

Phase II and Phase III (Integrated) EU CTIS Study details

MK-3508 Multiple Ascending Dose Study in Healthy Participants

Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

A clinical study of MK-3508 in healthy people (MK-3508-006)

Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

A study to learn how different amounts of the study medicine called PF-07941944 are tolerated in the body of healthy adults.

Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 2b, non-randomized, controlled, open-label, extension study to evaluate the persistence of immune response of the adjuvanted RSVPreF3 vaccine and the safety and immunogenicity following revaccination in lung and kidney transplant recipients (≥18 years of age)

Italy, Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Respiratory Syncytial Virus Infection trials by city

Respiratory Syncytial Virus Infection in Toronto Respiratory Syncytial Virus Infection in Vancouver Respiratory Syncytial Virus Infection in Montreal Respiratory Syncytial Virus Infection in Calgary Respiratory Syncytial Virus Infection in Edmonton Respiratory Syncytial Virus Infection in Ottawa Respiratory Syncytial Virus Infection in Winnipeg Respiratory Syncytial Virus Infection in Quebec City Respiratory Syncytial Virus Infection in Hamilton Respiratory Syncytial Virus Infection in Kitchener Respiratory Syncytial Virus Infection in London Respiratory Syncytial Virus Infection in Halifax Respiratory Syncytial Virus Infection in New York Respiratory Syncytial Virus Infection in Los Angeles Respiratory Syncytial Virus Infection in Chicago Respiratory Syncytial Virus Infection in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease